Circulating Transforming Growth Factor <I>&beta;</I>-1 Level in Japanese Patients With Marfan Syndrome

Abstract

SummaryMarfan syndrome (MFS) is an inherited connective tissue disorder mainly caused by the fi brillin-1 mutation. Deficient fi brillin-1 is thought to result in the failed sequestration of transforming growth factor β (TGFβ) and subsequent activation of the TGFβ signaling pathway, suggesting that the circulating TGFβ level may be elevated in MFS, although its accurate measurement is complex due to ex vivo release from platelet stores upon platelet activation. We measured the plasma TGFβ1 levels of 32 Japanese MFS patients (22 medically untreated, 10 treated, 20 males, 30.1 ± 9.6 years old) and 30 healthy volunteers (19 males, 29.5 ± 5.8 years old) by ruthenium-based electrochemiluminescence platform (ECL). PF4 was also measured by enzyme immunoassay (EIA) as a platelet degranulation marker. There was no significant difference in the mean plasma TGFβ1 level between the MFS group (1.31 ± 0.40 ng/mL) and controls (1.17 ± 0.33 ng/mL) (P = 0.16, NS). Also, there was no signifi cant difference between the untreated (1.24 ± 0.37 ng/mL) and treated (1.46 ± 0.45 ng/mL) MFS patients (P = 0.15, NS). We also measured PF4, which showed wide deviations but no significant difference between the two groups (P = 0.50). A difference in circulating TGFβ1 levels between MFS patients and controls was not detected in this Japanese population. Circulating TGFβ1 is not a diagnostic and therapeutic marker for Japanese MFS patients, although our fi ndings do not eliminate the possible association of TGFβ with the pathogenesis of MFS. (Int Heart J 2013; 54: 23-26)

Biomarkers for Diagnosis and Prognostic Stratification of Aortic Dissection: Challenges and Perspectives

“…Indeed, mutations in the FBN1 gene, present in most patients with Marfan syndrome, lead to deregulation of TGF-β bioavailability and to a consequent derangement in TGF-β autocrine and paracrine molecular signaling [24]. Evidence has also been provided that the circulating levels of TGF-β are increased in Marfan patients, although ethnic differences and technical issues may confound results [25][26][27]. Two studies have also reported higher levels of circulating TGF-β in patients with larger aortic diameter, faster aortic growth rate, previous aortic surgery and acute aortic events during follow-up, including Stanford type B AD and necessity of aortic replacement [26,28].…”

Marfan Syndrome in ophthalmology

“…Circulating TGFβ1 is not diagnostic and therapeutic marker for Japanese patients with Marfan syndrome, although ndings don't eliminate the possible association of TGFß with the pathogenesis of Marfan syndrome, what we have not been able to con rm nor exclude, due to technical limits in genetic examinations 4 .…”

Effect of Periodontitis on Cardiovascular Manifestations in Marfan Syndrome

“…24) Chaudhry, et al demonstrated that mutation of fibrillin-1 altered intercellular communication and significantly increased TGF-β protein levels in the extracellular space. 25) TGF-β is a paracrine regulatory molecule involved in several processes.…”